Assessment of Pharmacodynamic Effects of an Authorized Compound and a Novel Agent on Nerve Excitability in Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Study

The primary objective of this study is to assess the **pharmacodynamic** effects of an authorized compound and a new compound on nerve excitability threshold tracking in healthy male subjects. This evaluation is clinically relevant as it may provide insights into the potential therapeutic effects of these compounds in managing **neuropathic pain**. Understanding the impact on nerve excitability can contribute to the development of more effective treatments for this condition.

The clinical trial focuses on **neuropathic pain** and involves a study population consisting exclusively of male participants. The age range of the participants falls within the category code "3," which typically corresponds to adults, although specific age details are not provided. The trial does not include a vulnerable population, and the selection criteria for participants have not been disclosed by the sponsor. Additionally, there is no information available regarding the total number of participants, their general health status, or any lifestyle considerations such as diet or physical activity. The sponsor has not provided key inclusion or exclusion criteria for this study.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled**, three-way cross-over study aimed at assessing the pharmacodynamic effects of an authorized and a new compound on nerve excitability threshold tracking in healthy male subjects. The study targets **neuropathic pain** and is categorized as a Phase 3 trial. The estimated recruitment start date is May 6, 2024, with an anticipated end date of September 1, 2024, indicating a total trial duration of approximately four months.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into different treatment arms. The trial will include multiple follow-up visits to monitor the pharmacodynamic effects and ensure participant safety. These visits will be conducted in a double-blind manner, ensuring neither the participants nor the investigators are aware of the treatment allocations. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the outcomes of the interventions.

The expected length of participant involvement will span the entire trial duration, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The study is structured to maintain rigorous scientific standards while ensuring the safety and well-being of all participants throughout the trial period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 6, 2024, with an estimated completion date of September 1, 2024. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical standards to evaluate the efficacy of the intervention under investigation. The trial's design and execution will be aligned with the regulatory requirements for Phase 3 studies, focusing on generating robust and reliable efficacy data.